SAN DIEGO, Jan. 13, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, announced today preliminary unaudited gross product sales on sales of SUMAVEL® DosePro® for the quarter ended December 31, 2013. Zogenix expects to report fourth quarter 2013 gross product sales of approximately $14 million on 141,780 units shipped, with unit volume up approximately 2.2% sequentially from third quarter 2013.
Help employers find you! Check out all the jobs and post your resume.
